Praziquantel

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Praziquantel
   1. Pharmacist Assessment Report
   2. Praziquantel: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Praziquantel: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Praziquantel, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They are the drug’s own known uses, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	4
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
enterobiasis
opisthorchiasis
schistosomiasis
trichinosis

Australia Market Information

Licence	Product	Dosage form	Status
15199Y	Praziquantel Tablets, USP 600 mg (Endo, USA)	Tablet 600 mg (s19A)	Valid

Safety Considerations

• Contraindications suggested by the knowledge graph (not label text): epilepsy, liver disease, gallbladder disease, heart disease and cardiovascular disease.
• Drug Interactions: 83 interactions were identified. Those flagged Major in the data include:
  • Apalutamide
  • Phenobarbital
  • Carbamazepine

  Other listed interactions are Moderate (for example dexamethasone, bosentan, armodafinil, bexarotene, deferasirox) or Minor (cimetidine, albendazole). Enzyme-inducing drugs are a recurring theme.

Please refer to the TGA-approved Product Information (PI) for the full warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---